Stimulant Use Disorder

Understanding Stimulant Use Disorder

What It Is

Stimulant use disorder is a DSM-5 diagnosis applied when a pattern of stimulant use produces impaired control, social impairment, risky use, and pharmacological dependence over a 12-month period. It is graded mild, moderate, or severe by criteria count. DSM-5 specifies the substance — cocaine use disorder, amphetamine-type stimulant use disorder, or other stimulant use disorder — but the core diagnostic structure is identical.

What It Is Not

Therapeutic use of prescription stimulants for ADHD, as prescribed, is not stimulant use disorder. Many people with ADHD take stimulants daily for years without developing the disorder; effective ADHD treatment generally reduces substance use risk rather than increasing it. The disorder applies when stimulant use is non-prescribed, used in ways inconsistent with prescription, or produces the defined DSM-5 pattern of consequences.

The Reward Reality

Stimulants produce dopamine surges substantially larger than natural rewards. The pleasure of natural rewards — food, social connection, sex — can come to feel pale by comparison. Over time, this contrast produces anhedonia: a flattening of normal pleasure that is one of the hardest aspects of early recovery and one of the strongest drivers of relapse.

Who Develops It

Stimulant use disorder occurs across demographics, with risk elevated by family history, trauma, untreated ADHD or mood disorder, social environment, and certain occupational contexts. Methamphetamine and cocaine populations differ somewhat — methamphetamine use disorder is concentrated in particular geographic and demographic patterns, while cocaine use spans a broader social range.

DSM-5 Diagnostic Criteria

Stimulant use disorder requires 2 or more of the following 11 criteria within a 12-month period. As with other substances, tolerance and withdrawal do not count toward diagnosis when the stimulant is being taken solely under appropriate medical supervision.

Impaired Control

1. Stimulant taken in larger amounts or over longer period than intended
2. Persistent desire or unsuccessful efforts to cut down
3. Great deal of time spent obtaining, using, or recovering
4. Craving

Social Impairment

5. Recurrent use resulting in failure to fulfill major role obligations
6. Continued use despite persistent social or interpersonal problems
7. Important activities given up or reduced

Risky Use

8. Recurrent use in physically hazardous situations
9. Continued use despite persistent physical or psychological problems caused or worsened by stimulants

Pharmacological

10. Tolerance
11. Withdrawal — or stimulant used to relieve or avoid withdrawal

Severity

• Mild: 2–3 criteria
• Moderate: 4–5 criteria
• Severe: 6 or more criteria

Major Stimulants

Cocaine

A naturally occurring stimulant derived from the coca plant. Available as powder (insufflated, injected) and as crack (smoked). Effects last about 30 minutes to 1 hour for powder, much shorter for crack. Cocaine produces intense reward and rapidly leads to compulsive patterns of use in vulnerable individuals.

Methamphetamine

A synthetic stimulant. Smoked, snorted, injected, or swallowed. Effects last several hours to most of a day. Substantially more neurotoxic than cocaine, with elevated risk of stimulant-induced psychosis, severe dental damage ("meth mouth"), skin lesions from picking, and lasting cognitive effects. Methamphetamine binges can last days, with no sleep, leading to extreme medical and psychiatric instability.

Amphetamine and Prescription Stimulants

Amphetamine (Adderall), dextroamphetamine (Dexedrine), lisdexamfetamine (Vyvanse), methylphenidate (Ritalin, Concerta), and related compounds. These medications have substantial therapeutic value for ADHD and narcolepsy but are also misused — for academic performance, to stay awake, for weight loss, and recreationally. Non-prescribed use, use in higher doses than prescribed, or use via non-oral routes elevates risk.

MDMA

A substituted amphetamine with strong serotonergic effects. Often grouped with hallucinogens because of its empathogenic effects but classified as a stimulant. Acute hyperthermia and hyponatremia are the primary medical risks. MDMA-assisted therapy in clinical trials is distinct from recreational use of MDMA, which is often contaminated with other compounds.

Other Stimulants

Synthetic cathinones (bath salts), khat, pseudoephedrine, and various designer stimulants exist; risks vary widely.

Intoxication, Overdose, and Withdrawal

Acute Intoxication

• Euphoria, increased energy and alertness
• Elevated heart rate and blood pressure
• Pupillary dilation
• Reduced appetite
• Hyperthermia and sweating
• Tremor
• Talkativeness, grandiosity
• At high doses: agitation, paranoia, hallucinations, seizures

Overdose

Stimulant overdose can cause:

• Myocardial infarction
• Stroke (both ischemic and hemorrhagic)
• Aortic dissection
• Cardiac arrhythmia
• Severe hyperthermia leading to rhabdomyolysis and multi-organ failure
• Seizure
• Severe agitation requiring sedation

There is no specific antidote. Emergency management is supportive — benzodiazepines for agitation and seizures, cooling, blood pressure management. Fentanyl contamination of the illicit stimulant supply has substantially increased fatal overdose risk; naloxone is appropriate when overdose is suspected even if the user did not knowingly use opioids.

Withdrawal

Stimulant withdrawal is primarily psychological, though deeply unpleasant. The "crash" phase begins hours after stopping and includes:

• Profound fatigue and increased sleep
• Increased appetite
• Depressed mood, sometimes suicidal ideation
• Anhedonia
• Vivid, unpleasant dreams
• Intense craving

The acute crash typically resolves within a week. Post-acute withdrawal — anhedonia, low energy, mood instability, intermittent craving — can persist for weeks to months. This protracted phase is one of the strongest drivers of relapse.

Stimulant-Induced Psychosis

What It Is

Stimulant-induced psychotic disorder is a defined DSM-5 diagnosis involving hallucinations and/or delusions developing during or shortly after stimulant use that are sufficiently severe to warrant clinical attention. It is most commonly associated with methamphetamine, but cocaine and high-dose prescription stimulant misuse can also produce it.

Presentation

• Paranoid delusions, often persecutory
• Auditory hallucinations
• Tactile hallucinations — the classic "formication" or "meth bugs" — sensations of insects under the skin
• Disorganized thinking
• Hostility or fear-driven behavior

Course

Stimulant-induced psychosis typically resolves over hours to days with abstinence and supportive care. Antipsychotic medication may be needed acutely. In some users, repeated episodes lead to progressively faster onset of psychotic symptoms with smaller doses ("sensitization"). In a subset, psychosis persists or recurs even with abstinence, indicating a primary or substance-precipitated chronic psychotic disorder.

Implications

Any episode of stimulant-induced psychosis is a serious warning sign. Continued stimulant use after such an episode substantially elevates the risk of recurrent and progressively more severe psychotic episodes. Vulnerability to psychosis from any cause — family history, prior episodes — is a strong contraindication to stimulant use.

Medical Consequences

Cardiovascular

• Hypertension
• Myocardial infarction
• Cardiomyopathy (particularly methamphetamine-associated)
• Arrhythmias
• Aortic dissection
• Stroke

Neurological

• Seizures
• Stroke (both types)
• Cognitive impairment — particularly executive function and memory
• Possible accelerated Parkinson's risk with chronic methamphetamine use

Psychiatric

• Stimulant-induced psychosis (above)
• Severe depression, particularly during withdrawal
• Anxiety and panic
• Persistent anhedonia
• Increased suicide risk

Dermatological and Dental

• "Meth mouth" — severe dental erosion and tooth loss
• Skin lesions from picking and from skin breakdown
• Wound healing impairment

Infectious

Injection use raises risk of hepatitis B, hepatitis C, HIV, and endocarditis. Stimulant use is associated with elevated rates of sexually transmitted infections, particularly in the context of "chemsex" patterns.

Pregnancy

Prenatal stimulant exposure is associated with placental abruption, preterm birth, low birth weight, and possible neurodevelopmental effects. Pregnant individuals using stimulants need specialized prenatal and addiction care.

Causes and Risk Factors

Genetic

Heritability of stimulant use disorder is in the same range as other substance use disorders. Genetic variation in dopamine systems and broader substance vulnerability genes contribute.

Co-occurring Psychiatric Conditions

• ADHD — particularly when untreated
• Depression and bipolar disorder
• Anxiety disorders
• PTSD
• Other substance use disorders, particularly alcohol, opioids, cannabis, nicotine
• Personality disorders

Trauma

Adverse childhood experiences and trauma history are strongly associated with stimulant use disorder. Stimulants are often used to provide energy, focus, or numbing in the context of trauma sequelae.

Social and Environmental

• Peer use and norms
• Geographic and demographic patterns (varies by drug)
• Occupational environments where stimulant use is normalized
• Performance-pressure contexts (academic, professional)
• "Chemsex" and party-and-play contexts

Assessment

Screening

• TAPS and NIDA Quick Screen for general substance use
• Single-item screen: "How many times in the past year have you used an illegal drug or used a prescription medication for nonmedical reasons?"

Clinical Interview

Assessment covers substance type, quantity, frequency, route, source, duration of use, prior treatment, co-occurring substance use, psychiatric symptoms (including any history of psychosis), trauma history, medical history, and family history.

Medical Evaluation

• EKG
• Comprehensive metabolic panel and complete blood count
• Hepatitis and HIV screening
• Pregnancy testing
• Dental examination
• Cardiac assessment when chest pain history is present

Differential Diagnosis

• Primary psychotic disorder (schizophrenia spectrum)
• Bipolar disorder, particularly manic episodes
• Other substance use disorders
• Untreated ADHD presenting with attempts at self-medication
• Delirium from acute intoxication or withdrawal

Evidence-Based Treatment

Contingency Management

Contingency management — tangible rewards for verified abstinence — has the strongest evidence of any single intervention for stimulant use disorder. Rewards can be vouchers, prize draws, or cash; reinforcement schedules are designed to escalate with sustained abstinence. The intervention works because it directly addresses the reward deficits in early stimulant recovery. Despite strong evidence, contingency management has been underused in clinical practice because of regulatory and funding barriers; these are gradually being addressed.

Cognitive Behavioral Therapy

CBT for stimulant use disorder targets triggers, cravings, distorted thinking, and skill deficits. The Matrix Model is a well-known structured CBT-based program developed initially for methamphetamine use disorder. Group and individual formats both have evidence.

Community Reinforcement Approach (CRA)

CRA builds non-using reinforcers across life domains — relationships, work, recreation. Combined with vouchers, CRA + vouchers has particularly strong evidence in cocaine use disorder.

Motivational Interviewing

Brief, structured intervention building motivation for change. Often combined with CBT or contingency management.

Twelve-Step Facilitation

Cocaine Anonymous and Crystal Meth Anonymous provide structured peer-led recovery communities. Outcomes are comparable to CBT in many trials when engagement is sustained.

Pharmacotherapy

No medication is FDA-approved for cocaine or methamphetamine use disorder. Several have been studied with modest results:

• Bupropion (modest evidence in methamphetamine)
• Naltrexone, particularly in combination with bupropion
• Topiramate (some evidence in cocaine)
• Mirtazapine (some evidence in methamphetamine)
• Modafinil (mixed evidence)
• Stimulant agonist therapy (prescription stimulant substitution) — promising but not standard

Treatment of co-occurring conditions — ADHD, depression, anxiety, PTSD, other substance use disorders — is essential and often the most impactful pharmacological intervention.

Treating Co-occurring ADHD

Untreated ADHD is a common driver of stimulant misuse — including non-prescribed use of prescription stimulants. Evidence supports treating ADHD with prescription stimulants even in the context of substance use disorder, with careful clinical monitoring. Long-acting formulations (lisdexamfetamine, extended-release methylphenidate) and clinical structure reduce misuse risk substantially.

Harm Reduction

• Carry naloxone — fentanyl contamination makes opioid overdose possible even for stimulant users
• Avoid using alone
• Hydrate and stay cool, particularly in dance or party contexts
• Use new injection equipment if injecting
• Test substances when drug-checking services are available
• Avoid combining with alcohol (cocaethylene), opioids, or other depressants

Supporting a Loved One

What Helps

• Approach with compassion; stimulant withdrawal produces real, severe depression
• Recognize that early recovery anhedonia is biological, not laziness
• Encourage evidence-based treatment, particularly contingency management when available
• Carry naloxone and learn overdose response
• Take care of your own mental health; consider Nar-Anon or therapy

What to Avoid

• Confrontational interventions, which can backfire
• Treating psychosis-driven behavior as character
• Threats and ultimatums that you cannot keep
• Believing that one conversation will produce sustained change

When Psychosis Is Present

Stimulant-induced psychosis can produce frightening, paranoid behavior. Safety is the first priority. Avoid arguing with delusional content; speak calmly and concretely. Call for help if there is risk of harm. Symptoms typically resolve with abstinence and supportive care.